摘要
目前针对免疫相关疾病,尤其是免疫紊乱导致的自身免疫病以及变态反应性疾病,临床上的主要手段是利用甾体类和非甾体类以及其他免疫抑制剂进行治疗,没有针对疾病靶点的特异性治疗手段,同时由于免疫功能的缺乏,导致感染、肿瘤等副作用,其威胁程度甚至高于原发性疾病。近年来,由于多种免疫相关疾病发病机制和关键蛋白靶点的发现以及蛋白质降解靶向嵌合体(PROTAC)技术的逐步完善,越来越多的PROTAC药物被应用于免疫相关疾病的领域。本文聚焦免疫相关疾病的PROTAC药物,对其分子结构、降解效率及治疗效果进行总结概括,以期为免疫相关疾病的临床治疗及PROTAC的进一步发展提供一定的研究思路和参考。
At present,the main clinical approach for immune related diseases,especially autoimmune diseases and allergic diseases caused by immune disorders,is to use steroids,non steroids,and other immunosuppressants for treatment.There is no specific treatment for disease targets.Because of immune function deficiency,side effects such as infection or tumor may arise from immune impaired caused by these drugs,the threat level is even higher than the primary disease.In recent years,with the discovery of pathogenesis of immune related diseases and key protein targeting,and the improvement of chimeras targeting protein degradation(PROTAC)technology,more and more PROTAC drugs are applied in treating immune related diseases.This review focuses on PROTAC drugs for treating immune related diseases and the molecular structure,and degradation efficiency and treatment efficiency are mainly summarized,in order to provide reference and research idea for clinical treatment of immune related disease and development of PROTAC.
作者
肖琪
严树丽
李和桥
Xiao Qi;Yan Shuli;Li Heqiao(School of Medical Technology,Jiangmen Vocational College of Traditional Chinese Medicine,Jiangmen,Guangdong 529000,China;Shenzhen Bay Laboratory,Shenzhen,Guangdong 518132,China)
出处
《齐齐哈尔医学院学报》
2023年第22期2170-2175,共6页
Journal of Qiqihar Medical University
基金
江门市医疗卫生领域科技计划项目(2022YL05002)。
